Endoscopic Mucosal Resection in Barrett's Esophagus
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Barrett's Esophagus
- Sponsor
- Mayo Clinic
- Enrollment
- 1000
- Locations
- 1
- Primary Endpoint
- Number and types of adverse events in participants who have undergone endoscopic mucosal resection with documented adverse events will be evaluated for predictors of complications
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
Existing records will be reviewed to evaluate the predictors of complications including stricture formation, bleeding or perforation associated with endoscopic mucosal resection
Detailed Description
Barrett's esophagus (BE) is a complication of gastroesophageal reflux disease in which the normal squamous lining of the esophagus is replaced by specialized columnar epithelium.1 Approximately 5%-10% of patients diagnosed with BE are thought to be at risk of developing esophageal adenocarcinoma.2 Patients with high-grade dysplasia (HGD) on biopsy are at the greatest cancer risk³. EMR is being performed clinically in our Barrett's Esophagus Unit on a regular basis during endoscopy for patients with Barrett's Esophagus and/or early esophageal adenocarcinoma. There are two predominant endoscopic mucosal resection (EMR) techniques exist using FDA approved devices - the EMR cap method using a transparent cap/snare combination and the endoscopic variceal ligation method using a band ligator/snare combination to resect tissue.
Investigators
Cadman Leggett
Principal Investigator
Mayo Clinic
Eligibility Criteria
Inclusion Criteria
- •Barrett's Esophagus Early Esophageal Adenocarcinoma History of Endoscopic Mucosal Resection
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Number and types of adverse events in participants who have undergone endoscopic mucosal resection with documented adverse events will be evaluated for predictors of complications
Time Frame: 3 months after EMR procedure
analysis